Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.1M Buy
195,049
+1,830
+0.9% +$122K 0.03% 404
2026
Q1
$12.1M Sell
193,219
-24,961
-11% -$1.74M 0.03% 396
2025
Q4
$14.5M Sell
218,180
-83,562
-28% -$5.4M 0.03% 364
2025
Q3
$20.3M Sell
301,742
-31,960
-10% -$2.53M 0.05% 292
2025
Q2
$29.1M Buy
333,702
+37,171
+13% +$2.91M 0.07% 217
2025
Q1
$20.3M Buy
296,531
+77,883
+36% +$6.36M 0.06% 265
2024
Q4
$17M Buy
218,648
+52,344
+31% +$3.88M 0.05% 308
2024
Q3
$11.1M Buy
166,304
+3,374
+2% +$277K 0.04% 368
2024
Q2
$18.5M Sell
162,930
-42,793
-21% -$5.41M 0.07% 243
2024
Q1
$28.5M Buy
+205,723
New +$25.9M 0.09% 197

Other funds holding DXCM

Danske Bank's DXCM Position: Q2 2026 in Review

Danske Bank increased its DexCom (DXCM) stake by 0.95% in Q2 2026, buying an estimated $122K and bringing the position to 195,049 shares worth $13.1M. The position accounts for 0.03% of the portfolio, ranked #404.

Danske Bank first reported a position in DXCM in Q1 2024 and has held it in 10 quarters since. The position peaked at $29.1M in Q2 2025. 975 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Danske Bank held 195,049 shares of DexCom worth $13.1M as of Q2 2026.
  • Danske Bank bought 1,830 DexCom shares in Q2 2026, an estimated $122K.
  • DexCom made up 0.03% of Danske Bank's portfolio in Q2 2026, its #404 holding.
  • Danske Bank first reported a position in DexCom in Q1 2024 and has held it in 10 quarters since.
  • Danske Bank's DexCom position peaked at $29.1M in Q2 2025.
  • 975 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.